AstraZeneca

News
FDA clears AZ’s new PNH therapy Voydeya

FDA clears AZ’s new PNH therapy Voydeya

AstraZeneca’s Voydeya has become the first oral Factor D inhibitor to be approved by the FDA as a treatment for the rare disease paroxysmal nocturnal haemoglobinuria (PNH)

Patients
Case Study: MHRA and AstraZeneca
Sponsored

Case Study: MHRA and AstraZeneca

Agile, responsive regulation helps early breast cancer patients to benefit from a study to potentially improve survival outcomes.